Cidara Therapeutics/$CDTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Ticker

$CDTX
Sector
Primary listing

Employees

38

CDTX Metrics

BasicAdvanced
$2.7B
-
-$10.21
1.34
-

What the Analysts think about CDTX

Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.

Bulls say / Bears say

The Phase 2b NAVIGATE trial of CD388 achieved its main and all secondary efficacy goals, showing 76.1% protection at the 450 mg dose over 24 weeks, reducing risk for the asset before heading to Phase 3 (GlobeNewswire via Cidara Therapeutics).
Cidara completed an expanded public offering of 9.15 million shares at $44.00 each in June 2025, raising $402.5 million to finance its planned Phase 3 program, significantly strengthening its balance sheet (GlobeNewswire via Cidara Therapeutics).
Cidara's addition to the Russell 2000® and Russell 3000® indexes in June 2025 improves its visibility with institutional investors and could attract passive investment flows (GlobeNewswire via Cidara Therapeutics).
Research and development expenses rose sharply to $24.8 million in Q2 2025 from $6.7 million in Q2 2024, indicating a much faster cash burn as CD388 moves through costly late-stage development (GlobeNewswire via Cidara Therapeutics).
Collaboration revenue dropped to zero in Q2 2025 after the Janssen agreement ended in April 2024, highlighting the lack of recurring income and the company’s full reliance on equity financing for its operations (GlobeNewswire via Cidara Therapeutics).
Cidara posted a net loss of $25.7 million in Q2 2025, underlining continued unprofitability despite progress in the clinic and substantial fundraising (GlobeNewswire via Cidara Therapeutics).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

CDTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CDTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CDTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs